These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
573 related articles for article (PubMed ID: 30573759)
1. Immunotherapy in myasthenia gravis in the era of biologics. Dalakas MC Nat Rev Neurol; 2019 Feb; 15(2):113-124. PubMed ID: 30573759 [TBL] [Abstract][Full Text] [Related]
2. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Dalakas MC Curr Opin Neurol; 2020 Oct; 33(5):545-552. PubMed ID: 32833750 [TBL] [Abstract][Full Text] [Related]
3. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Dalakas MC Expert Rev Clin Immunol; 2022 Jul; 18(7):691-701. PubMed ID: 35730504 [TBL] [Abstract][Full Text] [Related]
4. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status. Beecher G; Putko BN; Wagner AN; Siddiqi ZA Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205 [TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Menon D; Bril V Drugs; 2022 Jun; 82(8):865-887. PubMed ID: 35639288 [TBL] [Abstract][Full Text] [Related]
6. Myasthenia gravis and specific immunotherapy: monoclonal antibodies. Cai XJ; Li ZW; Xi JY; Song HZ; Liu J; Zhu WH; Guo Y; Jiao Z Ann N Y Acad Sci; 2019 Sep; 1452(1):18-33. PubMed ID: 31393614 [TBL] [Abstract][Full Text] [Related]
7. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective. Suzuki S; Uzawa A; Murai H Expert Rev Clin Immunol; 2022 Dec; 18(12):1207-1215. PubMed ID: 36227228 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM; Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245 [TBL] [Abstract][Full Text] [Related]
9. [Novel immunomodulatory therapies in myasthenia gravis]. Sukockiené E; Théaudin M; Loser V; Staedler K; Lalive PH; Lascano AM Rev Med Suisse; 2024 Apr; 20(871):848-851. PubMed ID: 38665106 [TBL] [Abstract][Full Text] [Related]
10. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R; Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163 [TBL] [Abstract][Full Text] [Related]
12. Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience. Molimard A; Gitiaux C; Barnerias C; Audic F; Isapof A; Walther-Louvier U; Cances C; Espil-Taris C; Davion JB; Quijano-Roy S; Grisel C; Chabrol B; Desguerre I Neurology; 2022 Jun; 98(23):e2368-e2376. PubMed ID: 35314497 [TBL] [Abstract][Full Text] [Related]
13. Fc-Receptor Targeted Therapies for the Treatment of Keller CW; Pawlitzki M; Wiendl H; Lünemann JD Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071155 [No Abstract] [Full Text] [Related]
14. Ravulizumab for the treatment of myasthenia gravis. Vanoli F; Mantegazza R Expert Opin Biol Ther; 2023 Mar; 23(3):235-241. PubMed ID: 36852670 [TBL] [Abstract][Full Text] [Related]
16. Overview of myasthenia gravis. Arora Y; Li Y Hosp Pract (1995); 2013; 41(4):40-50. PubMed ID: 24145588 [TBL] [Abstract][Full Text] [Related]
17. Rituximab in Myasthenia Gravis - Where do we stand? Siddiqi ZA; Khan W; Hussain FS Expert Opin Biol Ther; 2021 Aug; 21(8):1013-1023. PubMed ID: 33566716 [No Abstract] [Full Text] [Related]
18. Efgartigimod alfa (Vyvgart) for myasthenia gravis. Med Lett Drugs Ther; 2022 Apr; 64(1648):62-63. PubMed ID: 35436776 [No Abstract] [Full Text] [Related]
19. Update on immune-mediated therapies for myasthenia gravis. Habib AA; Ahmadi Jazi G; Mozaffar T Muscle Nerve; 2020 Nov; 62(5):579-592. PubMed ID: 32462710 [TBL] [Abstract][Full Text] [Related]
20. Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod. Zhang C; Lin Y; Kuang Q; Li H; Jiang Q; Yang X Front Immunol; 2024; 15():1400459. PubMed ID: 38799457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]